Thymosin Alpha-1
A 28 amino acid peptide involved in T-cell maturation and immune modulation. Approved in several countries for hepatitis B treatment and immune boosting, though not in the US or EU. Thymosin alpha-1 is one of the most studied immune-modulating peptides in the research compound space.
Technical Context
Tα1 clinical evidence: approved in China for chronic hepatitis B (based on Chinese trials showing improved HBV DNA clearance and HBeAg seroconversion when combined with interferon-alpha), and used in various countries for immune support. Meta-analyses of Tα1 for hepatitis B show modest benefit as adjunct therapy. Investigated for: cancer immunotherapy enhancement (improving response rates to chemotherapy/immunotherapy in preliminary studies), sepsis-associated immunosuppression (improving immune cell function in critically ill patients), and COVID-19 (explored during the pandemic for immune modulation in severe cases). Limitations of the evidence base: many studies are small, single-centre, and conducted in countries with different regulatory standards; large, multicentre Phase III trials meeting FDA/EMA design standards have not been completed for most proposed indications.